NCT04221230: A reported trial by Neumora Therapeutics, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04221230 |
|---|---|
| Title | A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 3, 2020 |
| Completion date | April 8, 2022 |
| Required reporting date | April 8, 2025, midnight |
| Actual reporting date | April 4, 2025 |
| Date last checked at ClinicalTrials.gov | July 20, 2026 |
| Days late | None |